Nuevolution A/S, a Denmark-based drug discovery company, has appointed Paul Workman as scientific advisor. Professor Workman is the interim chief executive at the Institute of Cancer Research (ICR) in London, and director of its therapeutic unit, which he helped set up in 1997. He was previously head of the cancer bioscience section at AstraZeneca’s Alderley Park site, and is a co-founder of Piramed Pharma (Roche) and Chroma Therapeutics Ltd.
Prof. Workman has a BSc in biochemistry from the University of Leicester and a PhD in cancer pharmacology from the University of Leeds, both in the UK.
Nuevolution announced the appointment July 9.
Copyright 2014 Evernow Publishing Ltd